Research programme: anticancer antibodies - Cancer Research Technology/Roche Glycart
Latest Information Update: 18 Jun 2010
At a glance
- Originator Cancer Research UK
- Developer Cancer Research Technology; Cancer Research UK; Roche Glycart
- Class Antibodies
- Mechanism of Action Cell surface receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jan 2008 Preclinical trials in Cancer in United Kingdom (Parenteral)